Serum hepatitis B viral (HBV) DNA is a predictive biomarker for survival in non-small cell lung cancer patients with chronic HBV infection

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. doi:10.3322/caac.2138728055103
   PubMed Web of Science ®Google Scholar
• Sève P, Reiman T, Dumontet C. The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer. Lung Cancer. 2010;67(2):136–143. doi:10.1016/j.lungcan.2009.09.00719828208
   PubMed Web of Science ®Google Scholar
• Xie Y. Hepatitis B virus-associated hepatocellular carcinoma. Adv Exp Med Biol. 2017;1018:11–21. doi:10.1007/978-981-10-5765-6_229052129
   PubMed Web of Science ®Google Scholar
• Gomes M, Teixeira AL, Coelho A, et al. The role of inflammation in lung cancer. Adv Exp Med Biol. 2014;816(816):1–23.24818717
   PubMedGoogle Scholar
• Morrison WB. Inflammation and cancer: a comparative view. J Vet Intern Med. 2012;26(1):18–31. doi:10.1111/j.1939-1676.2011.00836.x22151229
   PubMed Web of Science ®Google Scholar
• Chang TS, Lee KF, Tung SY, et al. Abstract 1792: association of enhanced IGF-1R signaling and HBV/inflammation with poor HCC prognosis. Cancer Res. 2011;70(8 Supplement):1792. doi:10.1158/1538-7445.AM10-1792
   Google Scholar
• Wei XL, Qiu MZ, Chen WW, et al. The status of HBV infection influences metastatic pattern and survival in Chinese patients with pancreatic cancer. J Transl Med. 2013;11(1):249–257. doi:10.1186/1479-5876-11-24924099678
   PubMedGoogle Scholar
• Liu X, Li X, Jiang N, et al. Prognostic value of chronic hepatitis B virus infection in patients with nasopharyngeal carcinoma: analysis of 1301 patients from an endemic area in China. Cancer. 2014;120(1):68–76. doi:10.1002/cncr.2837724114075
   PubMed Web of Science ®Google Scholar
• Peng JW, Liu DY, Lin GN, et al. Hepatitis B virus infection is associated with poor prognosis in patients with advanced non small cell lung cancer. Asian Pac J Cancer Prev. 2015;16(13):5285–5288.26225667
   PubMedGoogle Scholar
• Ohkubo K, Kato Y, Ichikawa T, et al. Viral load is a significant prognostic factor for hepatitis B virus-associated hepatocellular carcinoma. Cancer. 2010;94(10):2663–2668. doi:10.1002/cncr.10557
   Google Scholar
• Mao YP, Xie FY, Liu LZ, et al. Re-evaluation of 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2009;73(5):1326–1334. doi:10.1016/j.ijrobp.2008.07.06219153016
   PubMed Web of Science ®Google Scholar
• Foucher P, Coudert B, Arveux P, et al. Age and prognosis of non-small cell lung cancer. Usefulness of a relative survival model. Eur J Cancer. 1993;29A(13):1809–1813.8260230
   PubMed Web of Science ®Google Scholar
• Salmerón D, Chirlaque MD, Izarzugaza MI, et al. Lung cancer prognosis in Spain: the role of histology, age and sex. Respir Med. 2012;106(9):1301–1308. doi:10.1016/j.rmed.2012.06.00622749756
   PubMed Web of Science ®Google Scholar
• Parsons A, Daley A, Begh R, et al. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ. 2010;340(7740):251–257. doi:10.1136/bmj.b5569
   Google Scholar
• Cavit C, Mustafa Fuat A, Ata O, et al. Prognostic impact of intratumoral C-reactive protein expression in patients with clear cell renal cell carcinoma. Urol Int. 2014;92(3):270–275. doi:10.1159/00035340124356040
   PubMed Web of Science ®Google Scholar
• Diem S, Schmid S, Krapf M, et al. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017;111:176–181. doi:10.1016/j.lungcan.2017.07.02428838390
   PubMed Web of Science ®Google Scholar
• Kawashima M, Murakawa T, Shinozaki T, et al. Significance of the Glasgow Prognostic Score as a prognostic indicator for lung cancer surgery. Interact Cardiovasc Thorac Surg. 2015;21(5):637–643. doi:10.1093/icvts/ivv22326269495
   PubMed Web of Science ®Google Scholar
• Iasonos A, Schrag D, Raj GV, et al. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364–1370. doi:10.1200/JCO.2007.12.979118323559
   PubMed Web of Science ®Google Scholar
• Galsky MD, Erin Moshier MS, Susan Krege MD, et al. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy. Cancer. 2013;119(16):3012–3019. doi:10.1002/cncr.2814623720216
   PubMed Web of Science ®Google Scholar
• Kim SH, Shin KH, Kim HY, et al. Postoperative nomogram to predict the probability of metastasis in Enneking stage IIB extremity osteosarcoma. BMC Cancer. 2014;14(1):1–10. doi:10.1186/1471-2407-14-124383403
   PubMedGoogle Scholar
• Lee CK, Goldstein D, Gibbs E, et al. Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. Eur J Cancer. 2015;51(7):852–860. doi:10.1016/j.ejca.2015.02.01525801699
   PubMed Web of Science ®Google Scholar
• Forrest L, McMillan D, McArdle C, et al. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003;89(6):1028–1030. doi:10.1038/sj.bjc.660124212966420
   PubMed Web of Science ®Google Scholar
• Pencina MJ, Da RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med. 2010;23(13):2109–2123. doi:10.1002/sim.1802
   Google Scholar
• Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56(2):337–344.10877287
   PubMed Web of Science ®Google Scholar
• Chen S, Lai Y, He Z, et al. Establishment and validation of a predictive nomogram model for non-small cell lung cancer patients with chronic hepatitis B viral infection. J Transl Med. 2018;16(1):116–125. doi:10.1186/s12967-018-1496-529728103
   PubMedGoogle Scholar
• Chen S, Li X, Lv H, et al. Prognostic dynamic nomogram integrated with inflammation-based factors for non-small cell lung cancer patients with chronic hepatitis B viral infection. Int J Biol Sci. 2018;14(13):1813–1821. doi:10.7150/ijbs.2726030443185
   PubMed Web of Science ®Google Scholar
• Zi-Xiong LI, Zhang Q, Lin J, et al. Possible mechanisms of malignant transformation of nonresolving inflammation caused by chronic infection with hepatitis B virus. Progr Biochem Biophys. 2014;41(1):9–16.
   Web of Science ®Google Scholar
• Yu LX, Ling Y, Wang HY. Role of nonresolving inflammation in hepatocellular carcinoma development and progression. Npj Precis Oncol. 2018;2(1):6–14. doi:10.1038/s41698-018-0048-z29872724
   PubMed Web of Science ®Google Scholar
• Nathan C, Ding A. Nonresolving inflammation. Cell. 2010;140(6):871–882. doi:10.1016/j.cell.2010.02.02920303877
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454(7203):436–444. doi:10.1038/nature0720518650914
   PubMed Web of Science ®Google Scholar
• Mason A, Wick M, White H, et al. Hepatitis B virus replication in diverse cell types during chronic hepatitis B virus infection. Hepatology. 2010;18(4):781–789. doi:10.1002/hep.1840180406
   Google Scholar
• Mitri MSD, Cassini R, Bernardi M. Hepatitis B virus-related hepatocarcinogenesis: molecular oncogenic potential of clear or occult infections. Eur J Cancer. 2010;46(12):2178–2186. doi:10.1016/j.ejca.2010.03.03420413301
   PubMed Web of Science ®Google Scholar
• Engels EA, Cho ERJee SH. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol. 2010;11(9):827–834. doi:10.1016/S1470-2045(10)70167-420688564
   PubMed Web of Science ®Google Scholar
• Chao W, Wen Y, He-Xin Y, et al. Hepatitis B virus X (HBx) induces tumorigenicity of hepatic progenitor cells in 3,5-diethoxycarbonyl-1,4-dihydrocollidine-treated HBx transgenic mice. Hepatology. 2012;55(1):108–120. doi:10.1002/hep.2467521932402
   PubMed Web of Science ®Google Scholar
• Yonghong L, Zhangwei T, Ting L, et al. Hepatitis B virus X protein stabilizes amplified in breast cancer 1 protein and cooperates with it to promote human hepatocellular carcinoma cell invasiveness. Hepatology. 2012;56(3):1015–1024. doi:10.1002/hep.2575122473901
   PubMed Web of Science ®Google Scholar
• Hou Z, Xu X, Fu X, et al. HBx-related long non-coding RNA MALAT1 promotes cell metastasis via up-regulating LTBP3 in hepatocellular carcinoma. Am J Cancer Res. 2017;7(4):845–856.28469957
   PubMed Web of Science ®Google Scholar
• Chen RC, Wang J, Kuang XY, et al. Integrated analysis of micro RNA and m RNA expression profiles in HBx-expressing hepatic cells. World J Gastroenterol. 2017;23(10):1787–1795. doi:10.3748/wjg.v23.i10.178728348484
   PubMed Web of Science ®Google Scholar
• Romero-Ventosa EY, Blanco-Prieto S, Gonzalez-Pineiro AL, et al. Pretreatment levels of the serum biomarkers CEA, CYFRA 21-1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients. Springerplus. 2015;4:171–183. doi:10.1186/s40064-015-0891-025918681
   PubMedGoogle Scholar
• Baek AR, Seo HJ, Lee JH, et al. Prognostic value of baseline carcinoembryonic antigen and cytokeratin 19 fragment levels in advanced non-small cell lung cancer. Cancer Biomark. 2018;22(1):1–8. doi:10.3233/CBM-17088529562492
   PubMed Web of Science ®Google Scholar